Minoryx Therapeutics

📍 Mataró, Spain🗓 Founded 2011👥 34 employees💰 Last funded 2021
Biotechnology🌐 minoryx.com
Website LinkedIn
Minoryx is a registration stage biotech company focusing on the development of novel therapies for orphan CNS diseases with high unmet medical needs. The company’s lead program, leriglitazone (MIN-102), a novel, brain penetrant and selective PPAR gamma agonist, is being developed in X-linked Adrenoleukodystrophy (X-ALD) and other orphan CNS diseases. The company is backed by a syndicate of experienced investors, which includes Columbus Venture Partners, CDTI Innvierte, Caixa Capital Risc, Fund+, Ysios Capital, Roche Venture Fund, Kurma Partners, Chiesi Ventures, S.R.I.W, Idinvest Partners / Eurazeo, SFPI-FPIM, HealthEquity, Sambrinvest and Herrecha, and has support from a network of other organizations. Minoryx was founded in 2011, is headquartered in Spain with Belgian facilities and has so far raised more than €120 million
6
Total investors
0
Early stage
3
Mid stage
3
Late stage
2011
Founded

Investors

6 investors
All
Early stage
Mid stage
Late stage
Investor geography3 countries
Spain
3
United States
1
Belgium
1
Investor activity2015–2021 · investors recorded per year
20153201812019120211
Recent (last 2y)Earlier
Frequently asked questions
Who invested in Minoryx Therapeutics?
Minoryx Therapeutics has 6 investors on record on gritt.io, 3 mid-stage and 3 late-stage investors.
When did Minoryx Therapeutics last raise funding?
The most recent investment in Minoryx Therapeutics recorded on gritt.io was in 2021.
When was Minoryx Therapeutics founded?
Minoryx Therapeutics was founded in 2011.
What industry is Minoryx Therapeutics in?
Minoryx Therapeutics operates in Biotechnology. Find similar Biotechnology investors on gritt.io.
Where is Minoryx Therapeutics based?
Minoryx Therapeutics is headquartered in Mataró, Spain.